- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06448754
Estudo exploratório da plataforma de fase II dos regimes de preparação Volrustomig (eVOLVE-01)
Um estudo aberto de fase II para avaliar a segurança, tolerabilidade, farmacocinética, imunogenicidade e atividade antitumoral de regimes de preparação de Volrustomig em combinação com outros agentes anticâncer em participantes com tumores sólidos (eVOLVE-01)
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Visão geral do estudo
Status
Condições
Descrição detalhada
This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Beijing, China, 100730
- Research Site
-
Hangzhou, China, 310014
- Research Site
-
Jinan, China, 250013
- Research Site
-
Yantai, China, 264000
- Research Site
-
Zhengzhou, China, 450000
- Research Site
-
-
-
-
-
Seongnam, Coréia do Sul, 13620
- Research Site
-
Seoul, Coréia do Sul, 03722
- Research Site
-
Suwon, Coréia do Sul, 16247
- Research Site
-
-
-
-
-
A Coruña, Espanha, 15009
- Research Site
-
Alcorcón, Espanha, 28922
- Research Site
-
Barcelona, Espanha, 08041
- Research Site
-
Madrid, Espanha, 28041
- Research Site
-
Málaga, Espanha, 29004
- Research Site
-
Pamplona, Espanha, 31008
- Research Site
-
Santander, Espanha, 39008
- Research Site
-
Santiago de Compostela, Espanha, 15706
- Research Site
-
Valencia, Espanha, 46026
- Research Site
-
Valencia, Espanha, 46015
- Research Site
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90067
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Research Site
-
-
-
-
-
Bois-Guillaume, França, 76031
- Research Site
-
Caen, França, 14076
- Research Site
-
Dijon, França, 21079
- Research Site
-
Montpellier, França, 34070
- Research Site
-
-
-
-
-
Batumi, Geórgia, 6010
- Research Site
-
Tbilisi, Geórgia, 0144
- Research Site
-
Tbilisi, Geórgia, 0112
- Research Site
-
Tbilisi, Geórgia, '0159
- Research Site
-
Tbilisi, Geórgia, 186
- Research Site
-
Tbilisi, Geórgia, 0114
- Research Site
-
-
-
-
-
Athens, Grécia, 115 27
- Research Site
-
Athens, Grécia, 12462
- Research Site
-
Elaiones, Grécia, 546 23
- Research Site
-
Piraeus, Grécia, 185 47
- Research Site
-
Thessaloniki, Grécia, 57001
- Research Site
-
-
-
-
-
Genoa, Itália, 16132
- Research Site
-
Meldola, Itália, 47014
- Research Site
-
Milan, Itália, 20133
- Research Site
-
Naples, Itália, 80131
- Research Site
-
Orbassano, Itália, 10043
- Research Site
-
Perugia, Itália, 06132
- Research Site
-
Rozzano, Itália, 20089
- Research Site
-
Udine, Itália, 33100
- Research Site
-
Verona, Itália, 37134
- Research Site
-
-
-
-
-
Kuala Lumpur, Malásia, 59100
- Research Site
-
Kuching, Malásia, 93586
- Research Site
-
Perai, Malásia, 13700
- Research Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Research Site
-
Lisbon, Portugal, 1169-050
- Research Site
-
Lisbon, Portugal, 1400-038
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
-
-
-
-
Cluj-Napoca, Romênia, 400641
- Research Site
-
Craiova, Romênia, 200542
- Research Site
-
Floreşti, Romênia, 407280
- Research Site
-
-
-
-
-
Geneva, Suíça, 1205
- Research Site
-
Lausanne, Suíça, 1011
- Research Site
-
Winterthur, Suíça, 8401
- Research Site
-
Zurich, Suíça, 8091
- Research Site
-
-
-
-
-
Belgrade, Sérvia, 11000
- Research Site
-
-
-
-
-
Changhua, Taiwan, 50006
- Research Site
-
New Taipei City, Taiwan, 23561
- Research Site
-
Taipei, Taiwan, 106
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
- Life expectancy greater than or equal to (>=) 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
- Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
- Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
- Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
- At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.
Key Exclusion Criteria:
- Spinal cord compression.
- History of primary active immunodeficiency.
- Active or prior documented autoimmune or inflammatory disorders.
- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
- Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Outros nomes:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Experimental: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Outros nomes:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Experimental: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel). |
Participants will receive volrustomig via intravenous (IV) infusion.
Outros nomes:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. Participants will receive ramucirumab via IV infusion. Participants will receive paclitaxel via IV infusion. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: From screening (Days -28 to Day -1) up to 2 year 10 months
|
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. |
From screening (Days -28 to Day -1) up to 2 year 10 months
|
|
Confirmed Objective Response rate (ORR)
Prazo: Up to 2 year 10 months
|
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). |
Up to 2 year 10 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Disease Control Rate (DCR)
Prazo: Up to 2 year 10 months
|
DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. |
Up to 2 year 10 months
|
|
Duration of Response (DOR)
Prazo: Up to 2 year 10 months
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Progression Free Survival (PFS)
Prazo: Up to 2 year 10 months
|
PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Overall Survival (OS)
Prazo: Up to 2 year 10 months
|
OS is defined as the time from randomization or first dose until the date of death due to any cause. |
Up to 2 year 10 months
|
|
Serum Concentration of Volrustomig
Prazo: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Trough concentration (Ctrough)
Prazo: Up to 2 year 10 months
|
The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Maximum Observed Concentration (Cmax)
Prazo: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Area Under the Curve (AUC)
Prazo: Up to 2 year 10 months
|
The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Number of Participants with Positive Antidrug Antibodies (ADAs)
Prazo: Up to 2 year 10 months
|
The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. |
Up to 2 year 10 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Respiratórias
- Doenças pulmonares
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Neoplasias Pulmonares
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Carcinoma pulmonar de células não pequenas
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Hidrocarbonetos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Terpenos
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Complexos de coordenação
- Guanina
- Hipoxantinas
- Purinonas
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Taxóides
- Ciclodecanos
- Diterpenos
- Pemetrexede
- Ramucirumabe
- Carboplatina
- Paclitaxel
Outros números de identificação do estudo
- D798KC00001
- 2023-509482-20-00 (Identificador de registro: CTIS)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.
Prazo de Compartilhamento de IPD
AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critérios de acesso de compartilhamento IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .